| Blockade of chronic type I interferon signaling to control persistent LCMV infection EB Wilson, DH Yamada, H Elsaesser, J Herskovitz, J Deng, G Cheng, ... Science 340 (6129), 202-207, 2013 | 801 | 2013 |
| The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections J Machhi, J Herskovitz, AM Senan, D Dutta, B Nath, MD Oleynikov, ... Journal of neuroimmune pharmacology 15, 359-386, 2020 | 734 | 2020 |
| Diagnostics for SARS-CoV-2 infections BD Kevadiya, J Machhi, J Herskovitz, MD Oleynikov, WR Blomberg, ... Nature materials 20 (5), 593-605, 2021 | 710 | 2021 |
| Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics MK Joubert, M Deshpande, J Yang, H Reynolds, C Bryson, M Fogg, ... PloS one 11 (8), e0159328, 2016 | 104 | 2016 |
| Amyloid precursor protein and amyloid precursor-like protein 2 in cancer P Pandey, B Sliker, HL Peters, A Tuli, J Herskovitz, K Smits, A Purohit, ... Oncotarget 7 (15), 19430, 2016 | 101 | 2016 |
| Nanocarrier vaccines for SARS-CoV-2 J Machhi, F Shahjin, S Das, M Patel, MM Abdelmoaty, JD Cohen, ... Advanced Drug Delivery Reviews 171, 215-239, 2021 | 92 | 2021 |
| Type I and type II interferon coordinately regulate suppressive dendritic cell fate and function during viral persistence CR Cunningham, A Champhekar, MV Tullius, BJ Dillon, A Zhen, ... PLoS pathogens 12 (1), e1005356, 2016 | 75 | 2016 |
| Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders J Machhi, BD Kevadiya, IK Muhammad, J Herskovitz, KE Olson, ... Molecular neurodegeneration 15, 1-26, 2020 | 65 | 2020 |
| CD4+ effector T cells accelerate Alzheimer’s disease in mice J Machhi, P Yeapuri, Y Lu, E Foster, R Chikhale, J Herskovitz, ... Journal of neuroinflammation 18, 1-23, 2021 | 57 | 2021 |
| HIV and the macrophage: from cell reservoirs to drug delivery to viral eradication J Herskovitz, HE Gendelman Journal of Neuroimmune Pharmacology 14, 52-67, 2019 | 48 | 2019 |
| A role for extracellular vesicles in SARS-CoV-2 therapeutics and prevention J Machhi, F Shahjin, S Das, M Patel, MM Abdelmoaty, JD Cohen, ... Journal of Neuroimmune Pharmacology 16, 270-288, 2021 | 43 | 2021 |
| CRISPR-Cas9 mediated exonic disruption for HIV-1 elimination J Herskovitz, M Hasan, M Patel, WR Blomberg, JD Cohen, J Machhi, ... EBioMedicine 73, 2021 | 31 | 2021 |
| Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues BD Kevadiya, B Ottemann, IZ Mukadam, L Castellanos, K Sikora, ... Theranostics 10 (2), 630, 2020 | 31 | 2020 |
| Creation of a long-acting rilpivirine prodrug nanoformulation JR Hilaire, AN Bade, B Sillman, N Gautam, J Herskovitz, BLD Shetty, ... Journal of controlled release 311, 201-211, 2019 | 28 | 2019 |
| A long acting nanoformulated lamivudine ProTide N Smith, AN Bade, D Soni, N Gautam, Y Alnouti, J Herskovitz, IM Ibrahim, ... Biomaterials 223, 119476, 2019 | 27 | 2019 |
| Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking IZ Mukadam, J Machhi, J Herskovitz, M Hasan, MD Oleynikov, ... Biomaterials 231, 119669, 2020 | 20 | 2020 |
| Synthesis of a long acting nanoformulated emtricitabine ProTide D Soni, AN Bade, N Gautam, J Herskovitz, IM Ibrahim, N Smith, ... Biomaterials 222, 119441, 2019 | 19 | 2019 |
| The immunopathobiology of SARS-CoV-2 infection M Patel, F Shahjin, JD Cohen, M Hasan, J Machhi, H Chugh, S Singh, ... FEMS Microbiology Reviews 45 (6), fuab035, 2021 | 14 | 2021 |
| Pharmacotherapeutics of SARS-CoV-2 infections BD Kevadiya, J Machhi, J Herskovitz, MD Oleynikov, WR Blomberg, ... Journal of Neuroimmune Pharmacology 16, 12-37, 2021 | 10 | 2021 |
| Immune suppression during preclinical drug development mitigates immunogenicity-mediated impact on therapeutic exposure J Herskovitz, J Ryman, T Thway, S Lee, L Zhou, N Chirmule, B Meibohm, ... The AAPS journal 19, 447-455, 2017 | 10 | 2017 |
